Autolus Therapeutics (AUTL) Jefferies London Healthcare Conference 2024 summary

Regulatory and clinical milestones

• Achieved U.S. approval for Aucatzyl on November 8, following extensive engagement with MHRA and FDA, including site inspections and manufacturing process validation.

• Approval was granted a week ahead of the PDUFA date, with a favorable label and no REMS requirement, a first in the field.

• Demonstrated robust safety and efficacy data, even in highly immunocompromised and older patient populations, with a median age of 51 years.

• Event-free survival rate of 65% in a subset of patients, with overall efficacy at least as good as existing therapies and improved safety.

• European and U.K. regulatory reviews are ongoing, with launches planned in these regions by the end of next year.

Commercial strategy and launch plans

• Initial U.S. launch targets 30 centers, expanding to 60 centers covering over 90% of eligible patients by next year.

• Center activation involves extensive preparation, including reimbursement, logistics, and training, typically taking 6–12 months per center.

• Full commercial readiness expected in Q1, with comprehensive support services for centers and patients.

• Product priced between $562,000 and $582,000, justified by superior safety profile and reduced overall treatment costs.

Manufacturing and operational readiness

• Manufacturing process designed for consistency despite variable patient cell quality, with over 500 full-scale runs completed for robustness.

• Facility can produce up to 2,800 batches per year, leveraging automation and parallel processing for individualized therapies.

• Facility was built and validated over three years, ensuring supply chain resilience and cost efficiency.